Clinical Trials Browser

Terminated × Disease Progression × ublituximab × Clear all

NCT04149821 2023-06-15

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Phase 2 Terminated

1 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Disease Progression